[Genetic polymorphisms as new predictive factors for successful treatment of chronic hepatitis C].
Currently, the gold standard for the treatment of chronic hepatitis C is combination therapy with pegylated interferon alpha and ribavirin. Despite advances in treatment modalities, only 50 % of patients achieve sustained virological response. Therefore, determination of predictive factors related to response to therapy is very important. In 2009, three independent studies concerning genome-wide association identified several single nucleotide polymorphisms near the IL-28 gene, associated with virological response. Hence, it appears that genetic polymorphism may become important predictive factors. All patients beginning therapy, will probably be tested for the presence of these polymorphisms, allowing individualized treatment options for every patient.